Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Advanced Squamous Non-Small Cell Lung Cancer

Interventions: Biological: AMG 479
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-12-12

Last Posted Date: 2017-03-29

Lead Sponsor: NantCell, Inc.

Target Recruit Count: 49

Registration Number: NCT00807612

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer

Phase 1

Completed

Conditions: Cervical Cancer

Interventions: Drug: carboplatin
Drug: topotecan hydrochloride

First Posted Date: 2008-12-11

Last Posted Date: 2014-10-29

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 12

Registration Number: NCT00807079

Locations: 🇫🇷
Hotel Dieu de Paris, Paris, France

Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Drug: CS7017 tablets
Drug: Carboplatin
Drug: Paclitaxel
Drug: Placebo Tablets

First Posted Date: 2008-12-10

Last Posted Date: 2020-05-13

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 111

Registration Number: NCT00806286

Locations: 🇺🇸
Michiana Hematology-Oncology, South Bend, Indiana, United States
🇺🇸
Southern Illinois Hematology/Oncology, Centralia, Illinois, United States
🇺🇸
Signal Point Clinical Research Center, Middletown, Ohio, United States

and more 24 locations

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: erlotinib [Tarceva]
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2008-12-02

Last Posted Date: 2014-11-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT00800202

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: pemetrexed disodium

First Posted Date: 2008-11-26

Last Posted Date: 2017-01-25

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 65

Registration Number: NCT00798603

Locations: 🇺🇸
Illinois CancerCare - Princeton, Princeton, Illinois, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

and more 212 locations

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

Phase 1

Completed

Conditions: Advanced Melanoma

Interventions: Drug: Ipilimumab
Drug: Dacarbazine
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-11-24

Last Posted Date: 2014-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 72

Registration Number: NCT00796991

Locations: 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸
H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States
🇺🇸
Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States

and more 1 locations

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cediranib maleate
Other: placebo
Drug: paclitaxel

First Posted Date: 2008-11-21

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 306

Registration Number: NCT00795340

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 16 locations